Head-to-head evidence
pumecitinib vs Ruxolitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK1/2 · full Atopic Dermatitis pipeline
pumecitinib
Developed by Prime Gene Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Ruxolitinib
Marketed by Incyte
NCT03745638 · Phase 3 · completed
This was a randomized, quadruple-blinded, vehicle-controlled Phase 3 trial with 631 participants, comparing two doses of ruxolitinib cream against placebo. The primary endpoint was a clinician-assessed measure of disease severity (IGA treatment success at Week 8), and the comparison was met decisively: both ruxolitinib groups achieved significantly higher response rates than vehicle (50.0% and 53.8% vs 15.1%, each p<0.0001). The sample size was adequate, treatment assignment was concealed, and the hard clinical endpoint clearly favored active treatment.
Next expected readout: August 2027 · NCT07661979 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: pumecitinib's landscape · Ruxolitinib's landscape